Xanthogranulomatous epithelial tumor: report of 6 cases of a novel, potentially deceptive lesion with a predilection for young women.


Journal

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
ISSN: 1530-0285
Titre abrégé: Mod Pathol
Pays: United States
ID NLM: 8806605

Informations de publication

Date de publication:
10 2020
Historique:
received: 17 03 2020
accepted: 24 04 2020
revised: 23 04 2020
pubmed: 18 5 2020
medline: 3 8 2021
entrez: 17 5 2020
Statut: ppublish

Résumé

Epithelial marker expression and/or epithelial differentiation, as well as "anomalous" expression of keratins, are features of some soft tissue tumors. Recently, we have encountered an unusual mesenchymal tumor composed of bland, distinctly eosinophilic, keratin-positive epithelial cells, which were almost entirely obscured by xanthogranulomatous inflammation. Six cases were identified (5 F, 1 M; 16-62 years (median 21 years)) arising in soft tissue (n = 4) and bone (n = 2) and ranging in size from 2 to 7 cm. The tumors were generally circumscribed, with a fibrous capsule containing lymphoid aggregates, and consisted in large part of a sheet-like proliferation of foamy histiocytes, Touton-type and osteoclast-type giant cells, and chronic inflammatory cells. Closer inspection, however, disclosed a distinct population of uniform, cytologically bland mononuclear cells with brightly eosinophilic cytoplasm arranged singly and in small nests and cords. Overt squamous and/or glandular differentiation was absent. By immunohistochemistry, these cells were diffusely positive with the OSCAR and AE1/AE3 keratin antibodies, and focally positive for high-molecular weight keratins; endothelial and myoid markers were negative and SMARCB1 was retained. RNA-seq identified a PLEKHM1 variant of undetermined significance in one case, likely related to this patient's underlying osteopetrosis. Follow-up to date has been benign. In summary, we have identified a novel tumor of soft tissue and bone with a predilection for young females, provisionally termed "xanthogranulomatous epithelial tumor". These unusual lesions do not appear to arise from adnexa, or represent known keratin-positive soft tissue tumors, and the origin of their constituent epithelial cells is obscure. The natural history of this distinctive lesion appears indolent, although study of additional cases and longer term follow-up are needed.

Identifiants

pubmed: 32415263
doi: 10.1038/s41379-020-0562-8
pii: S0893-3952(22)00459-8
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1889-1895

Références

Miettinen M, Fetsch JF. Distribution of keratins in normal endothelial cells and a spectrum of vascular tumors: implications in tumor diagnosis. Hum Pathol. 2000;31:1062–7.
doi: 10.1053/hupa.2000.9843
Remotti F, Fetsch JF, Miettinen M. Keratin 1 expression in endothelia and mesenchymal tumors: an immunohistochemical analysis of normal and neoplastic tissues. Hum Pathol. 2001;32:873–9.
doi: 10.1053/hupa.2001.26466
Miettinen M. Immunoreactivity for cytokeratin and epithelial membrane antigen in leiomyosarcoma. Arch Pathol Lab Med. 1988;112:637–40.
pubmed: 2454091
Ramaekers FC, Pruszczynski M, Smedts F. Cytokeratins in smooth muscle cells and smooth muscle tumours. Histopathology. 1988;12:558–61.
doi: 10.1111/j.1365-2559.1988.tb01979.x
Brown DC, Theaker JM, Banks PM, Gatter KC, Mason DY. Cytokeratin expression in smooth muscle and smooth muscle tumours. Histopathology. 1987;11:477–86.
doi: 10.1111/j.1365-2559.1987.tb02656.x
Miettinen M, Rapola J. Immunohistochemical spectrum of rhabdomyosarcoma and rhabdomyosarcoma-like tumors. Expression of cytokeratin and the 68-kD neurofilament protein. Am J Surg Pathol. 1989;13:120–32.
doi: 10.1097/00000478-198902000-00005
Coindre JM, de Mascarel A, Trojani M, de Mascarel I, Pages A. Immunohistochemical study of rhabdomyosarcoma. Unexpected staining with S100 protein and cytokeratin. J Pathol. 1988;155:127–32.
doi: 10.1002/path.1711550209
Fritchie KJ, Torres-Mora J, Inwards C, Thway K, Vaiyapuri S, Jackson R, et al. Xanthogranulomatous Epithelial Tumor: report of 6 cases of a novel, potentially deceptive lesion with a predilection for young women. Mod Pathol. 2020;USCAP Los Angeles CA, Abstract #676.
Davila JI, Fadra NM, Wang X, McDonald AM, Nair AA, Crusan BR, et al. Impact of RNA degradation on fusion detection by RNA-seq. BMC Genomics. 2016;17:814.
doi: 10.1186/s12864-016-3161-9
Winters JL, Davila JI, McDonald AM, Nair AA, Fadra N, Wehrs RN, et al. Development and verification of an RNA sequencing (RNA-Seq) assay for the detection of gene fusions in tumors. J Mol Diagn. 2018;20:495–511.
doi: 10.1016/j.jmoldx.2018.03.007
Wang C, Davila JI, Baheti S, Bhagwate AV, Wang X, Kocher JP, et al. RVboost: RNA-seq variants prioritization using a boosting method. Bioinformatics. 2014;30:3414–6.
doi: 10.1093/bioinformatics/btu577
Gown AM, Vogel AM. Monoclonal antibodies to human intermediate filament proteins. II. Distribution of filament proteins in normal human tissues. Am J Pathol. 1984;114:309–21.
pubmed: 6320650 pmcid: 1900342
Gown AM, Vogel AM. Monoclonal antibodies to human intermediate filament proteins. III. Analysis of tumors. Am J Clin Pathol. 1985;84:413–24.
doi: 10.1093/ajcp/84.4.413
Collini P, Sampietro G, Bertulli R, Casali PG, Luksch R, Mezzelani A, et al. Cytokeratin immunoreactivity in 41 cases of ES/PNET confirmed by molecular diagnostic studies. Am J Surg Pathol. 2001;25:273–4.
doi: 10.1097/00000478-200102000-00022
Gu M, Antonescu CR, Guiter G, Huvos AG, Ladanyi M, Zakowski MF. Cytokeratin immunoreactivity in Ewing’s sarcoma: prevalence in 50 cases confirmed by molecular diagnostic studies. Am J Surg Pathol. 2000;24:410–6.
doi: 10.1097/00000478-200003000-00010
Bridge JA, Fidler ME, Neff JR, Degenhardt J, Wang M, Walker C, et al. Adamantinoma-like Ewing’s sarcoma: genomic confirmation, phenotypic drift. Am J Surg Pathol. 1999;23:159–65.
doi: 10.1097/00000478-199902000-00004
Folpe AL, Goldblum JR, Rubin BP, Shehata BM, Liu W, Dei Tos AP, et al. Morphologic and immunophenotypic diversity in Ewing family tumors: a study of 66 genetically confirmed cases. Am J Surg Pathol. 2005;29:1025–33.
pubmed: 16006796
Dardick I, Schatz JE, Colgan TJ. Osteogenic sarcoma with epithelial differentiation. Ultrastruct Pathol. 1992;16:463–74.
doi: 10.3109/01913129209057831
Hasegawa T, Shibata T, Hirose T, Seki K, Hizawa K. Osteosarcoma with epithelioid features. An immunohistochemical study. Arch Pathol Lab Med. 1993;117:295–8.
pubmed: 7680195
Cupp JS, Miller MA, Montgomery KD, Nielsen TO, O’Connell JX, Huntsman D, et al. Translocation and expression of CSF1 in pigmented villonodular synovitis, tenosynovial giant cell tumor, rheumatoid arthritis and other reactive synovitides. Am J Surg Pathol. 2007;31:970–6.
doi: 10.1097/PAS.0b013e31802b86f8
West RB, Rubin BP, Miller MA, Subramanian S, Kaygusuz G, Montgomery K, et al. A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells. Proc Natl Acad Sci USA. 2006;103:690–5.
doi: 10.1073/pnas.0507321103
Van Wesenbeeck L, Odgren PR, Coxon FP, Frattini A, Moens P, Perdu B, et al. Involvement of PLEKHM1 in osteoclastic vesicular transport and osteopetrosis in incisors absent rats and humans. J Clin Invest. 2007;117:919–30.
doi: 10.1172/JCI30328
Bo T, Yan F, Guo J, Lin X, Zhang H, Guan Q, et al. Characterization of a relatively malignant form of osteopetrosis caused by a novel mutation in the PLEKHM1 gene. J Bone Min Res. 2016;31:1979–87.
doi: 10.1002/jbmr.2885
Almarzooqi S, Reed S, Fung B, Boue DR, Prasad V, Pietryga D. Infantile osteopetrosis and juvenile xanthogranuloma presenting together in a newborn: a case report and literature review. Pediatr Dev Pathol. 2011;14:307–12.
doi: 10.2350/10-09-0909-CR.1

Auteurs

Karen J Fritchie (KJ)

Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, 55905, USA.

Jorge Torres-Mora (J)

Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, 55905, USA.

Carrie Inwards (C)

Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, 55905, USA.

Khin Thway (K)

Sarcoma Unit, Royal Marsden Hospital, London, UK.

Sumathi Vaiyapuri (S)

The Royal Orthopaedic Hospital Trust Foundation, London, UK.

Rory Jackson (R)

Department of Medical Genetics, Mayo Clinic, Rochester, MN, 55905, USA.

Kay Minn (K)

Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, 55905, USA.

Kevin Halling (K)

Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, 55905, USA.

Carola Arndt (C)

Department of Pediatric Hematology/Oncology, Mayo Clinic, Rochester, MN, 55905, USA.

Matthew T Houdek (MT)

Department of Orthopedics, Mayo Clinic, Rochester, MN, 55905, USA.

Doris E Wenger (DE)

Department of Radiology, Mayo Clinic, Rochester, MN, 55905, USA.

Richard Curry (R)

Department of Neurology, TriHealth Physicians Partners, Cincinnati, OH, 45229, USA.

Seshadri Thirumala (S)

Department of Pathology, Ameripath and Texas Tech University Medical School, Lubbock, TX, 79430, USA.

Cyril Fisher (C)

University Hospitals Birmingham NHS Foundation Trust, Birmingham, B15 2TT, UK.

Jaime Davila (J)

Department of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, 55905, USA.

Andrew L Folpe (AL)

Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, 55905, USA. folpe.andrew@mayo.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH